FBRX vs GANX

Forte Biosciences, Inc. vs Gain Therapeutics, Inc. — Valuation Comparison 2026

FBRX

Pharmaceutical Preparations
Forte Biosciences, Inc.
Quality
4.1
out of 10
Value Trap
18
SAFE
Price
$19.07
Last close
Models
9/13
Active
VS

GANX

Pharmaceutical Preparations
Gain Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
32
LOW
Price
$1.95
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType FBRX Fair ValueFBRX Upside GANX Fair ValueGANX Upside
Bayesian DCF Intrinsic $6.88 -63.9% $0.65 -66.9%
Earnings Power Value Intrinsic $6.28 -77.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.39 -82.2% $0.47 -75.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FBRX vs GANX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FBRX vs GANX — Which Stock Is More Undervalued?

GANX scores higher with a 4.3/10 quality rating vs FBRX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Forte Biosciences, Inc. (FBRX) and Gain Therapeutics, Inc. (GANX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FBRX currently trades at $19.07 with a QOC of 4.1/10, while GANX trades at $1.95 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).